We studied the role of IL4 in human IgE formation in severe combined immunodeficient mice engrafted with peripheral blood mononuclear leukocytes (hu-PBL-SCID). PBL from four nonatopic donors produced only small (< 20 ng/ml) or undetectable amounts of IgE in SCID mice whereas engrafted PBL from seven atopic donors secreted IgE with IgE serum levels reaching a mean±SE of 184±37 ng/ml (n = 20). Serum IgE levels peaked 2-3 wk after PBL transfer and declined thereafter with a half-life of 1-2 wk. In contrast, IgG of all subclasses reached maximum serum levels 5-7 wk after PBL transfer and declined little thereafter. Injection of a neutralizing monoclonal antibody to the human IL4 receptor (IL4R) on day 0 inhibited completely the IgE formation and caused an approximate twofold reduction of IgG production of all subclasses. The anti-IL4 R antibody had no effect on IgE secretion when administered 4 wk after PBL engraftment. Incubation of PBL with IL4 before engraftment resulted in a 10-fold increase in IgE production and could be further enhanced by 100 fold if, in addition to preincubation with IL4, IL4 was injected daily for 5 d after PBL transfer. This treatment with IL4 also induced two-to threefold increase in IgG levels. IFN-'y had no effect on either IgE or IgG subclass production. In 50% of the mice, one or more IgG subclasses increased disproportionally 5 wk after PBL injection as a result of monoclonal IgG formation. These data demonstrate that PBL from atopic donors secrete IgE in SCID mice in an IL4-dependent manner, and that IgE production can be enhanced 10-to 100-fold with exogenous human IL4 in these mice. This mouse model is amenable for the in vivo study of immunomodulators on human IgE formation.(J. Clin. Invest. 1994.93:711-717.)
Introduction
We studied the role of IL4 in human IgE formation in severe combined immunodeficient mice engrafted with peripheral blood mononuclear leukocytes (hu-PBL-SCID). PBL from four nonatopic donors produced only small (< 20 ng/ml) or undetectable amounts of IgE in SCID mice whereas engrafted PBL from seven atopic donors secreted IgE with IgE serum levels reaching a mean±SE of 184±37 ng/ml (n = 20). Serum IgE levels peaked 2-3 wk after PBL transfer and declined thereafter with a half-life of 1-2 wk. In contrast, IgG of all subclasses reached maximum serum levels 5-7 wk after PBL transfer and declined little thereafter. Injection of a neutralizing monoclonal antibody to the human IL4 receptor (IL4R) on day 0 inhibited completely the IgE formation and caused an approximate twofold reduction of IgG production of all subclasses. The anti-IL4 R antibody had no effect on IgE secretion when administered 4 wk after PBL engraftment. Incubation of PBL with IL4 before engraftment resulted in a 10-fold increase in IgE production and could be further enhanced by 100 fold if, in addition to preincubation with IL4, IL4 was injected daily for 5 d after PBL transfer. This treatment with IL4 also induced two-to threefold increase in IgG levels. IFN-'y had no effect on either IgE or IgG subclass production. In 50% of the mice, one or more IgG subclasses increased disproportionally 5 wk after PBL injection as a result of monoclonal IgG formation. These data demonstrate that PBL from atopic donors secrete IgE in SCID mice in an IL4-dependent manner, and that IgE production can be enhanced 10-to 100-fold with exogenous human IL4 in these mice. This mouse model is amenable for the in vivo study of immunomodulators on human IgE formation.(J. Clin. Invest. 1994 .93:711-717.) Key words:IgEformation * IgG subclasses * human SCID mouse chimeras * interleukin4 * interleukin4 receptor A portion of this manuscript has been presented at the meetings of the Federation of American Societies of Experimental Biology, 5-9 April 1993, Anaheim, CA, and published in abstract form (1992. FASEB C.B-17 severe combined immunodeficient scid/scid (SCID)' mice (1) engrafted with human PBL (hu-PBL-SCID) produce relatively large amounts of human Ig (2) (3) (4) (5) (6) . The predominant isotype of the human Ig in hu-PBL-SCID mice is IgG with smaller quantities of IgM and IgA (3, 4) . The IgG consists of both polyclonal IgG (4) and specific antibodies (5) (6) (7) (8) (9) (10) with the latter especially being the case if the donor has been recently immunized (2) or if the PBL are incubated with antigen in vitro followed by immunization of the mice (6) . PBL from autoimmune patients also secrete specific antibodies in hu-PBL-SCID mice ( 1 1-13 ) . Therefore, the hu-PBL-SCID mouse model has great promise for studying the regulation of human Ig formation under in vivo conditions.
Recently, much has been learned regarding IgE regulation. IL-4 together with a second B cell activation signal ( 14, 15, reviewed in 16) induces the IgM to IgE switch and subsequent IgE secretion in vitro. IFN-,y as well as other lymphokines ( 14, 15) inhibit this process. However, little is known ofthe effect of these lymphokines on human IgE secretion in vivo. In clinical trials designed to evaluate a possible downregulatory effect of IFN--y on IgE antibody formation and allergic disease manifestations, no significant effect of IFN--y on the IgE serum level was observed ( 17, 18) . Because new immunomodulators such as lymphokines can initially not be tested in man for ethical reasons, an animal model of human IgE formation would be desirable to obtain preclinical data on the effect of immunomodulators on human IgE formation in vivo. Saxon et al. ( 19) reported low or undetectable IgE serum levels in hu-PBL-SCID mice. The reason for this may be the low frequency of circulating IgE committed memory B cells in peripheral blood and/or the rare occurrence of the IgM to IgE switch in nonatopic humans. Ito et al. (20) showed that, in contrast to PBL from nonatopic patients, PBL from atopic donors secrete IgE in SCID mice, perhaps because B cells from atopics more readily switch to IgE than do B cells from nonatopics. In this study, we also investigated whether PBL from atopic humans would secrete IgE after transfer into SCID mice. In addition, we determined whether the IgE formation in hu-PBL-SCID mice is IL-4 dependent and whether culturing of PBL with human IL-4 and injection of IL-4 into the mice would increase the IgE production. We show that PBL from atopic donors secrete relatively large amounts of IgE in SCID mice, which is dependent on IL-4 production and its interaction with high affinity IL-4 receptors. This IgE production can be enhanced further with exogenous IL-4 treatment. Thus, SCID mice engrafted with PBL from atopic donors can serve as an animal model for studying human IgE formation in vivo.
Methods
Mice. C.B-17 scid/scid immunodeficient mice were bred and maintained at the Children's Hospital Oakland Research Institute ( 10) or the Animal Facilities of the University California at San Diego. Mice were housed in sterilized microbarrier units with sterilized bedding. They were provided autoclaved chow and water. To eliminate a small percent of "leaky" mice (21 ) , the mice were bled and the mouse IgM and IgG serum level determined. Only mice having < 5 ng mouse IgM/ml or < 1 ,ug IgG/ml were used for the experiments.
Human subjects and PBL isolation. PBL were isolated from heparinized peripheral venous blood by centrifugation through Ficoll-Hypaque and washed in RPMI 1640 medium containing 10% FCS. Blood from normal subjects was obtained from four adult volunteers who had no history of atopic disorders. The atopic donors consisted of four males and three females. Three had a history of atopic dermatitis and/ or asthma and allergic rhinitis but were healthy at the time of blood donation. Four patients had active atopic dermatitis and had not taken oral corticosteroids for 2 24 h before blood donation. Informed consent was obtained from all donors. PBL IL-4 and IFN-,y. IL-4 was isolated from culture supernatants of Chinese hamster ovary cells transfected with human IL-4 DNA. The cell supernatant was concentrated 50-fold by ultrafiltration and subjected to ion-exchange chromatography on S-Sepharose FF (Pharmacia Fine Chemicals, Piscataway, NJ) in 20-mM sodium citrate buffer at pH 5.5. IL-4 was eluted from the column with starting buffer containing 800 mM sodium chloride. Active fractions were pooled and subjected to reversed-phase chromatography on a C4 column (VYDAC, Hesperia, CA) equilibrated with 0.1% trifluoroacetic acid. IL-4 was eluted by gradient elution with acetonitrile containing 0.1% trifluoroacetic acid. The isolated recombinant IL-4 showed one band in SDS-PAGE, gave a single peak in analytical reversed-phase HPLC, and it had a bioactivity of I0 7 U /mg when tested for half-maximum proliferation of human T cells suboptimally activated with phytohemagglutinin. 5 h after injection of 10 ,ug IL-4 i.p. into normal mice, the IL-4 serum level was -600 ng/ml and declined thereafter with a half-life of 20 min. 24 h after intraperitoneal injection of the IL-4, the serum contained < 30 pg IL-4 /ml. The IL-4 levels were measured with a modified radioimmunoassay (22) using two monoclonal antibodies to IL-4 prepared in our laboratory. A monoclonal murine IgG 1 anti-IL-4 receptor antibody (M57) was isolated from cultured hybridoma cells supernatant by absorption to a protein A-Sepharose 4B column (23). Recombinant IFN-,y (Genentech, Inc., South San Francisco, CA) for human use was a gift from Dr. John Bastian (Children's Hospital, San Diego, CA).
IgE and IgG subclass determinations. Mice were bled from the retroorbital venous plexous and the blood was allowed to clot. The serum was then collected and stored at -20°C. The IgE and IgG serum levels were determined by radioimmunoassays previously described (22 and serum dilutions were incubated overnight, and the amount of IgE or IgG subclasses bound to the plates was detected with either purified goat anti-IgE or anti-IgG prepared in our laboratory. The sensitivity of the RIA was 0.4 ng IgE/ml and 0.2-0.8 ng IgG for the different IgG subclasses. Electrophoresis of undiluted serum was performed on cellulose acetate membranes with a Beckman Instruments (Carlsbad, CA) electrophoresis apparatus as previously described for human myeloma sera (24) .
Statistical analyses. The data were analyzed statistically by the Student's t test.
Results
Human IgE production in SCID mice engrafted with PBLfrom nonatopic and atopic donors. 22 SCID mice were injected with PBL from four nonatopic donors, and 61 SCID mice were injected with PBL from seven atopic donors. Of these mice, seven injected with PBL from either nonatopic or atopic donors had < 100 yg IgG/ml, whereas the others had > 2.5 mg IgG/ml.
The mice with low IgG levels were considered as poorly engrafted and were not studied further. The IgE levels in 18 mice injected with PBL from nonatopic donors were < 20 ng/ml. In contrast, all mice injected with PBL from the atopic donors had easily measurable IgE with a mean±SE maximum serum level of 184±37 ng/ml (range = 29-997 ng/ml) in 20 mice injected with PBL from 7 atopic donors. Considerable variation in IgE serum levels was observed between mice injected with PBL from different donors and also between different mice injected with PBL from the same donor. As shown in Fig.  1 ., mice engrafted with PBL from an atopic dermatitis patient produced low levels of IgE as early as 1 wk after PBL injection, and peak serum levels were reached 2-3 wk after PBL engrafting. After 2-3 wk, the IgE levels declined with a half-life of 1-2 wk. No correlation was observed between the peak IgE serum level in the mice and either the donor's atopic disease activity, IgE serum level or the IgE spontaneously secreted by the donor's PBL cultured in vitro for 10 d (data not shown). Whereas the IgE serum levels typically declined in most mice after reaching a maximum level 2-3 wk after the PBL injection, in one exceptional mouse, the IgE level rose from about 250 ng/ml to 2,000-3,000 ng/ml between weeks 5 and 7 ( Fig. 2) and remained at this level < 14 wk after the PBL engraftment when the mouse was killed. As described below for IgG subclasses, this increase was most likely the result of a monoclonal expansion of IgE producing B cells in this mouse.
IgG subclass levels in hu-PBL-SCID mice engrafted with PBLfrom nonatopic and atopic donors. All hu-PBL-SCID mice produced the four subclasses of IgG. The sum of the four IgG (Table I) . On average, the mice injected with PBL from atopic donors had higher total IgG and higher IgG subclass levels than mice injected with PBL from nonatopic donors, but this difference was not significant (P > 0.05).
The proportion of the four IgG subclasses in the hu-PBL-SCID mice remained relatively constant for 5-7 wk. Thereafter, one or two IgG subclasses increased disproportionally in about half of the mice. This is shown in Fig. 4 for a hu-PBL-SCID mouse, which after 5 wk showed a marked increase in the IgG 1 level that by week 7 exceeded the levels of the other subclasses by nearly 100-fold. This increase was the result of a clonal expansion of IgG producing B cells as shown by monoclonal bands in serum electrophoresis (Fig. 5) Two control mice that had high IgE serum levels were injected 4 wk after the PBL engraftment with 1 mg anti-IL-4R antibody to determine whether this antibody inhibited ongoing IgE formation. Injection of this antibody had no effect on the slowly declining IgE level in these mice.
Effect of IL-4 on the IgE and IgG subclass formation in hu-PBL-SCID mice. PBL from the two atopic donors, who were free of disease at the time of blood donation, were preincubated with 500 U IL-4/ml for 24 h before injection into SCID mice. In addition, four mice were injected with 10 tg IL-4 i.p. daily for 5 d after the PBL graft. As shown in Fig. 6 , the four mice injected with IL-4 attained a mean IgE serum level of 1 1,900 ng IgE/ml, which is 100-fold higher than in the control mice. The IgE level in the control mice reached a maximum 3 wk after PBL engraftment, whereas the maximum IgE level in IL-4-treated mice occurred 6 wk after grafting. Also, the IgE level in the IL-4-treated mice declined only slowly thereafter with a half-life of 5-6 wk as compared to 1-2 wk for the controls. Preincubation of the PBL from the same donors with IL-4 but without subsequent injection of IL-4 into mice, also enhanced IgE production (mean±SE peak serum level of 1,120±230 ng/ml IgE) but not to the extent observed with in vivo IL-4 treatment (Table III) .
Three hu-PBL-SCID mice were injected on days 28-32 with 10 ,g IL-4 i.p. IgE levels did not increase in any of these The lack of IgE formation in hu-PBL-SCID mice grafted with cells from nonatopics confirms previous observations ( 19, 20) and suggests that cells from nonatopic subjects contain no or few memory B cells that become activated to secrete IgE in SCID mice, nor do they have B cells that undergo an IgM to IgE switch in the mice. In contrast, PBL from atopic donors spontaneously secreted IgE after transfer into SCID mice, which has (20) . The kinetics of IgE formation in the SCID mice differed for untreated and IL-4 exposed PBL. IgE produced by untreated PBL reached peak serum levels 2-3 wk after the PBL graft and declined thereafter with a half-life of 1-2 wk. In contrast, the IgE level reached peak values 4-5 wk after engraftment of IL-4-treated PBL, and the IgE serum level declined slowly with a half-life of -6 wk. These findings suggest that PBL from atopic patients contain B cells that, upon transfer into SCID mice, are capable of maturing rapidly into IgE secreting cells but are relatively short lived in the absence of exogenous IL-4. The reason for this is unknown. Perhaps these cells secrete IgE for only a brief period because of a lack ofcontinuous stimulation in the SCID mice. Spontaneous human antibody production ceases soon after the PBL transfer into SCID mice if the cells are not first activated with antigen or if the mice are not subsequently immunized (6, 7, 10) . Perhaps both IgE and IgG secretion that occurs after the engraftment of PBL into SCID mice is derived from relatively short-lived B cells. Continuous Ig secretion appears to require antigenic stimulation and T cell activation.
IL-4 not only induced IgE formation, but also enhanced
IgG production by two-to threefold in the hu-PBL-SCID mice.
In vitro, IL-4 induces IgE and IgG4 secretions (22, (26) (27) (28) .
Although the IgG4 levels were increased in hu-PBL-SCID mice injected with IL-4, the increase was statistically not significant. The IgG subclass distribution in hu-PBL-SCID mice 3-5 wk after the PBL graft was similar to that of normal human serum. Thereafter, one or two IgG subclasses increased rapidly and disproportionately in -50% of the mice. A similar rapid increase in the IgE level occurred in one mouse, although it reached only 3 ,ug/ml as compared to 2-8 mg IgG/ml. This restricted increase appears to be the result of a monoclonal expansion ofB cells as shown by monoclonal spikes in cellulose acetate electrophoresis, similar to those seen in patients with monoclonal gammopathy (24) . Such monoclonal bands have also been observed in the hu-PBL-SCID mice by others, although they often are referred to as oligoclonal peaks (4, 7, 30, 31 ) . Saxon et al. ( 19) showed that the IgG K/X ratio is skewed in many SCID mice 2 5 wk after the PBL injection. These investigators interpreted the abnormal K/X ratios as the result of a limited number of B cell clones that successfully engrafted in the SCID mice. Our findings demonstrate that the initial IgG subclass distribution is similar to that in normal human serum and that a skewing of the IgG subclass ratios occurs only 5 wk after the PBL engrafting. This result suggests that PBL in SCID mice initially mainly produce polyclonal Ig, but at later times, a limited number of B cells expand monoclonally causing the skewed IgG subclass and K/X ratios. Monoclonal expansion may result from expansion of EBV-transformed B cells, although monoclonal Ig has also been observed in hu-PBL-SCID mice grafted with PBL from EBV-negative donors (30, 31 ) . No overt lymphomas were detected upon autopsy in our mice after terminating the experiments indicating that the monoclonal B cell expansion was limited in mass. Alternatively, monoclonal expansion could result from selective activations of B cells reactive with mouse tissue antigens (7) . Perhaps the growth of these B cells is under T cell control. It was shown that the T cells decrease to a small number several weeks after the PBL engraftment (32) . This may allow the B cells to expand in a monoclonal manner. As shown by Ito et al. (20) , two of three mice injected with CD8-depleted PBL from an atopic donor showed a sudden increase in the IgE level 5-6 wk after PBL transfer, whereas this was not the case in the three control mice receiving unfractionated PBL. This suggests that CD8 + T cells may inhibit the monoclonal Ig formation. Interestingly, a human SCID patient who was given a bone marrow graft also showed monoclonal Ig including IgE, which disappeared after a second graft that resulted in T cell engraftment (33) .
The objective of this study was to define the conditions for human IgE secretion in hu-PBL-SCID mice. By using PBL from atopics and exposing the cells to IL-4, we have shown that PBL secrete large quantities of IgE for a long period of time in SCID mice. Most likely this IgE is polyclonal in nature. However, in a small percentage of mice it is possible that monoclonal IgE production can occur 5-6 wk after PBL injection. Therefore, the hu-PBL-SCID model involving PBL from atopic patients is most useful for studying the effect ofimmunomodulators on IgE formation during the first 5 wk of engraftment. This is illustrated by the effects of an anti-IL-4 receptor antibody and of IFN-y on the IgE secretion in hu-PBL mice. The anti-IL-4R antibody completely inhibited all IgE secretion during the initial weeks after PBL injection. Although IFN-'y inhibits IL-4-induced IgE secretion in vitro ( 14, 15), it did not inhibit the IgE formation in the hu-PBL-SCID mice. This is analogous to the lack of an effect of IFN-y on the IgE serum levels in atopic patients ( 17, 18) . This concordant ineffectiveness of IFN-y on IgE secretion in vivo demonstrates that immunoregulators of human IgE formation have to be tested in vivo, such as in hu-atopic-PBL-SCID mice, to evaluate their possible beneficial therapeutic effect in man.
